Antiaging Quantu Financials
This page shows Antiaging Quantu (AAQL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Antiaging Quantu passes 3 of 9 financial strength tests. No profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Antiaging Quantu generates $1.25 in operating cash flow (-$900K OCF vs -$720K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Antiaging Quantu generated $818K in revenue in fiscal year 2025. This represents an increase of 10806.8% from the prior year.
Antiaging Quantu's EBITDA was -$646K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 59.0% from the prior year.
Antiaging Quantu reported -$720K in net income in fiscal year 2025. This represents a decrease of 74.4% from the prior year.
Antiaging Quantu earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 73.9% from the prior year.
Cash & Balance Sheet
Antiaging Quantu held $371K in cash against $0 in long-term debt as of fiscal year 2025.
Antiaging Quantu had 30M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Antiaging Quantu's gross margin was 52.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 37.3 percentage points from the prior year.
Antiaging Quantu's operating margin was -96.6% in fiscal year 2025, reflecting core business profitability. This is up 5411.1 percentage points from the prior year.
Antiaging Quantu's net profit margin was -88.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5418.9 percentage points from the prior year.
Capital Allocation
AAQL Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $340K0.0% | $340K-12.8% | $390K+33.9% | $291K+1.1% | $288K+86.6% | $154K-10.8% | $173K-14.3% | $202K |
| Cost of Revenue | $136K0.0% | $136K+107.6% | $66K+15.8% | $57K-84.7% | $370K+7064.4% | $5K-64.1% | $14K+8610.9% | $165 |
| Gross Profit | $204K0.0% | $204K-37.2% | $324K+38.2% | $235K+388.0% | -$81K-154.6% | $149K-6.0% | $159K-21.3% | $202K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $401K0.0% | $401K+16.2% | $345K-4.2% | $360K+53.2% | $235K-17.2% | $284K+10.8% | $256K-10.0% | $285K |
| Operating Income | $272K+200.0% | -$272K-431.5% | -$51K+62.9% | -$138K+23.0% | -$179K+9.7% | -$199K-0.5% | -$198K+7.6% | -$214K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $550.0% | $55-99.5% | $10K+74.1% | $6K | N/A | N/A | N/A | N/A |
| Net Income | $272K+200.0% | -$272K-341.8% | -$62K+53.8% | -$133K+25.7% | -$180K-39.1% | -$129K+34.7% | -$198K+7.6% | -$214K |
| EPS (Diluted) | $0.01+200.0% | $-0.01-309.5% | $-0.00+53.3% | $-0.00 | N/A | $-0.00+34.8% | $-0.01+7.0% | $-0.01 |
AAQL Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.8M0.0% | $1.8M-4.9% | $1.9M+13.8% | $1.7M+5.2% | $1.6M+0.8% | $1.6M+97.7% | $797K-24.1% | $1.1M |
| Current Assets | $1.3M0.0% | $1.3M+3.8% | $1.2M+19.8% | $1.0M+25.9% | $811K+22.9% | $660K+291.0% | $169K-49.3% | $333K |
| Cash & Equivalents | $937K0.0% | $937K+105.7% | $455K+12.3% | $406K+9.5% | $371K+83.0% | $202K+441.4% | $37K-69.5% | $123K |
| Inventory | $102K0.0% | $102K+41.0% | $72K | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $86K | N/A | $468K+69.3% | $276K+222.0% | $86K+255.0% | $24K-17.6% | $29K-72.1% | $105K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.5M-28.5% | $2.1M-34.8% | $3.2M+10.0% | $2.9M+8.3% | $2.7M+331.0% | $631K-61.5% | $1.6M-2.2% | $1.7M |
| Current Liabilities | $1.4M0.0% | $1.4M+15.3% | $1.2M+31.8% | $910K+34.2% | $678K+85.3% | $366K-68.3% | $1.2M+5.0% | $1.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $301K+200.0% | -$301K+77.5% | -$1.3M-5.1% | -$1.3M-12.5% | -$1.1M-219.5% | $946K+212.3% | -$842K-34.7% | -$625K |
| Retained Earnings | $1.9M+200.0% | -$1.9M-17.0% | -$1.6M-4.0% | -$1.5M-9.5% | -$1.4M-14.6% | -$1.2M-11.7% | -$1.1M-21.9% | -$903K |
AAQL Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $255K-26.5% | $346K+272.7% | $93K+150.3% | -$185K+44.5% | -$333K+3.3% | -$344K-3576.3% | -$9K+95.6% | -$214K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $162K+5454.6% | $3K+101.8% | -$164K-14982.8% | -$1K+94.1% | -$19K-123300.0% | -$15+99.9% | -$15K+48.8% | -$30K |
| Financing Cash Flow | $460K+283.3% | $120K0.0% | $120K-45.5% | $220K-57.6% | $519K+1.6% | $511K+936.1% | -$61K-130.6% | $200K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AAQL Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.9%0.0pp | 59.9%-23.2pp | 83.2%+2.6pp | 80.5%+108.8pp | -28.3%-124.9pp | 96.7%+5.0pp | 91.7%-8.2pp | 99.9% |
| Operating Margin | 80.0%+160.0pp | -80.0%-66.9pp | -13.1%+34.3pp | -47.4%+14.9pp | -62.3%+66.4pp | -128.7%-14.5pp | -114.2%-8.3pp | -105.9% |
| Net Margin | 80.0%+160.0pp | -80.0%-64.2pp | -15.8%+30.0pp | -45.8%+16.6pp | -62.3%+21.3pp | -83.6%+30.6pp | -114.2%-8.3pp | -105.9% |
| Return on Equity | 90.5% | N/A | N/A | N/A | N/A | -13.7% | N/A | N/A |
| Return on Assets | 15.0%+30.1pp | -15.0%-11.8pp | -3.2%+4.7pp | -8.0%+3.3pp | -11.3%-3.1pp | -8.2%+16.6pp | -24.8%-4.4pp | -20.4% |
| Current Ratio | 0.920.0 | 0.92-0.1 | 1.02-0.1 | 1.12-0.1 | 1.20-0.6 | 1.80+1.7 | 0.15-0.2 | 0.30 |
| Debt-to-Equity | 5.02+12.0 | -7.02-4.6 | -2.43-0.1 | -2.32+0.1 | -2.41-3.1 | 0.67+2.6 | -1.95+0.7 | -2.68 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Frequently Asked Questions
What is Antiaging Quantu's annual revenue?
Antiaging Quantu (AAQL) reported $818K in total revenue for fiscal year 2025. This represents a 10806.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Antiaging Quantu's revenue growing?
Antiaging Quantu (AAQL) revenue grew by 10806.8% year-over-year, from $7K to $818K in fiscal year 2025.
Is Antiaging Quantu profitable?
No, Antiaging Quantu (AAQL) reported a net income of -$720K in fiscal year 2025, with a net profit margin of -88.1%.
What is Antiaging Quantu's EBITDA?
Antiaging Quantu (AAQL) had EBITDA of -$646K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Antiaging Quantu's gross margin?
Antiaging Quantu (AAQL) had a gross margin of 52.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Antiaging Quantu's operating margin?
Antiaging Quantu (AAQL) had an operating margin of -96.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Antiaging Quantu's net profit margin?
Antiaging Quantu (AAQL) had a net profit margin of -88.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Antiaging Quantu's operating cash flow?
Antiaging Quantu (AAQL) generated -$900K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Antiaging Quantu's total assets?
Antiaging Quantu (AAQL) had $1.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Antiaging Quantu's current ratio?
Antiaging Quantu (AAQL) had a current ratio of 1.20 as of fiscal year 2025, which is considered adequate.
What is Antiaging Quantu's debt-to-equity ratio?
Antiaging Quantu (AAQL) had a debt-to-equity ratio of -2.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Antiaging Quantu's return on assets (ROA)?
Antiaging Quantu (AAQL) had a return on assets of -45.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Antiaging Quantu's cash runway?
Based on fiscal year 2025 data, Antiaging Quantu (AAQL) had $371K in cash against an annual operating cash burn of $900K. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Antiaging Quantu's debt-to-equity ratio negative or unusual?
Antiaging Quantu (AAQL) has negative shareholder equity of -$1.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Antiaging Quantu's Piotroski F-Score?
Antiaging Quantu (AAQL) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Antiaging Quantu's earnings high quality?
Antiaging Quantu (AAQL) has an earnings quality ratio of 1.25x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.